Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL

February 21st 2025

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL

February 20th 2025

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant

February 16th 2025

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies

February 16th 2025

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies

February 15th 2025

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent

February 14th 2025

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment

February 14th 2025

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Orca-T With RIC Is Safe in Advanced Hematologic Malignancies

February 14th 2025

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Axatilimab, Ruxolitinib, and Belumosudil Combo Elicits Responses in Chronic GVHD

February 14th 2025

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.

P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma

February 14th 2025

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

Obe-Cel Is Associated With Improved Outcomes in R/R B-ALL With Low-Risk CAR-HT Scores

February 13th 2025

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis

February 13th 2025

The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.

Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024

February 11th 2025

The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in 2024.

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 2/2

February 8th 2025

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

February 7th 2025

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.